Clinical trial

Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity

Recruiting now · Not applicable · 1 countries · Registry ID NCT07541677

Recruiting nowNot applicableObservational

What this study is about

Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%. In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups. The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments. Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age21 Years to 100 Years

SexAll

Healthy volunteersNot accepted

ConditionObesity

Full registry criteria

Inclusion Criteria: * body mass index ≥ 27.5kg/m2 * able to provide informed consent. Exclusion Criteria: * unable to undergo the physical function tests (handgrip strength testing and chair-stand tests) * pregnant women * history of bariatric procedures or surgeries * on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

SarcopeniaOutcome measures will be recorded at baseline only.

Skeletal muscle mass Skeletal muscle mass measurement will be obtained via bioimpedance analysis using the TANITA MC 780 MA Multi-frequency Segmental Body Composition Analyser. Low skeletal muscle mass will be defined by percentage of skeletal muscle mass divided by body weight of ≤ 37% in males and ≤ 27.6% in females.

Handgrip strengthOutcome measures will be recorded at baseline only.

Handgrip strength will be measured using the Jamar handgrip dynamometer. Two trials will be performed for each hand, and the maximum strength will be used for diagnosis.

5-time chair stand testOutcome measures will be recorded at baseline only.

Time taken (seconds) to perform 5 sit-to-stand repetitions

30-second sit-to-stand testOutcome measures will be recorded at baseline only.

Number of sit-to-stand repetitions performed in 30 seconds

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Singapore General Hospital🇸🇬 Singapore, Singapore

Open map

Sarah Tan Dr, MBBSContact

Email · Call +6581239629